Padakonn Pharma has been selected to join the UK Government’s Global Entrepreneur Programme (GEP), marking an important milestone in the company’s international growth. The programme will support Padakonn Pharma as it strengthens its presence in the United Kingdom and expands collaborations across the country’s life sciences and innovation ecosystem.
GEP is a flagship initiative of the UK Department for Business and Trade for ambitious international scale-ups looking to establish a UK headquarters or R&D presence, combining strategic mentoring with practical support for UK market integration and access to relevant commercial, research, and investor networks. Padakonn Pharma looks forward to contributing to the UK’s vibrant biotech ecosystem through new collaborations.
Padakonn Pharma is an Estonian biotechnology company developing a monoclonal antibody platform for fibrosis-related diseases. The company’s goal is to translate research in MBG biology and vascular fibrosis into targeted therapies that protect vascular function and address the mechanisms associated with chronic kidney disease and other vascular conditions.